Nanobiotix (NBTX.US) Surges Over 700% Amid Acquisition Interest from Johnson & Johnson (JNJ.US)

Nanobiotix (NBTX.US) Shares Surge Following Report of Potential Acquisition by Johnson & Johnson

Paris-based Nanobiotix collaborates with global healthcare leader Johnson & Johnson. Under a long-term licensing agreement signed in 2023 with the New Jersey-based pharmaceutical company Johnson & Johnson, they are jointly developing and commercializing the next-generation core asset JNJ-1900 (NBTXR3).

Last October, the company's stock price surged significantly due to preliminary results from a Phase 1 clinical trial; the trial aimed to evaluate this intratumoral injection therapy as a crucial component of a combination treatment regimen for a type of esophageal cancer known as locally advanced esophageal adenocarcinoma.

In the just-passed 2025, Nanobiotix's stock price and market value increased by more than 700%, bringing its latest market value to approximately 1.5 billion US dollars.

Nanobiotix is essentially a French late-stage clinical oncology biotech company. Its core focus is not on traditional small molecules or antibody drugs but on developing a "physics mechanism-driven nanotechnology tumor treatment platform." Its most important core asset is NBTXR3/JNJ-1900: a candidate product composed of functionalized hafnium oxide nanoparticles. After a single intratumoral injection into the tumor, it enhances energy deposition within the tumor under radiotherapy exposure, thereby improving the efficiency of radiotherapy in killing tumor cells while minimizing additional radiation damage to surrounding normal tissues.

The company's main business line at present revolves around this large "radiosensitization/radioenhancement" platform, advancing clinical development in multiple solid tumors such as head and neck cancer, lung cancer, esophageal cancer, and pancreatic cancer. It aims to establish it as a foundational technology for cancer treatment that can be expanded across different types of cancers. In 2025, the company has continuously released positive clinical signals, which is the core reason behind its stock price surging by 700% over the past year. For instance, preliminary Phase I data in esophageal cancer showed good treatment tolerance, with an 85% disease control rate and a 69% objective response rate among 13 patients. The company is also concurrently advancing in indications such as pancreatic cancer and lung cancer.

In 2023, Janssen, a subsidiary of Johnson & Johnson, signed a global co-development and commercialization licensing agreement with Nanobiotix. In March 2025, the two parties revised the agreement, under which Nanobiotix is no longer responsible for funding the pivotal Phase III head and neck cancer study NANORAY-312. The cash visibility period has been extended until mid-2026, significantly alleviating the most critical financing pressure faced by clinical-stage biotech companies. If the asset JNJ-1900 or the Phase III head and neck cancer data, along with subsequent multi-cancer data, continues to be positive, Johnson & Johnson's direct acquisition would be more advantageous than long-term profit-sharing in terms of gaining global rights, pricing power, and expanding into additional indications. This means that what attracts Johnson & Johnson to Nanobiotix is not just a single product, but rather the potential of its physical nano-therapy platform, which could be scaled up to become a new paradigm for enhancing cancer radiotherapy.